#BEGIN_DRUGCARD DB03995

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C42H70O35

# Chemical_IUPAC_Name:
(1S,3R,5S,6S,8S,10R,11S,13S,15S,16S,18S,20S,21S,23S,25S,26S,28S,30S,31S,33S,35S,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.2^{3,6}.2^{8,11}.2^{13,16}.2^{18,21}.2^{23,26}.2^{28,31}]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Carcinogens
Food Additives

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Cyclo-Hepta-Amylose

# HET_ID:
BCD

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C42H70O35/c43-1-8-29-15(50)22(57)36(64-8)72-30-9(2-44)66-38(24(59)17(30)52)74-32-11(4-46)68-40(26(61)19(32)54)76-34-13(6-48)70-42(28(63)21(34)56)77-35-14(7-49)69-41(27(62)20(35)55)75-33-12(5-47)67-39(25(60)18(33)53)73-31-10(3-45)65-37(71-29)23(58)16(31)51/h8-63H,1-7H2/t8-,9-,10-,11-,12-,13-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36-,37-,38-,39+,40-,41-,42-/m0/s1

# InChI_Key:
InChIKey=WHGYBXFWUBPSRW-RUPPEMBSSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3995

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
1134.9842

# Molecular_Weight_Mono:
1134.36976401

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1GVI

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.3

# Predicted_LogS:
-0.1

# Predicted_Water_Solubility:
9.10e+02 g/l

# Primary_Accession_No:
DB03995

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936858

# PubChem_Substance_ID:
46505830

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00638

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@H]1O[C@H]2O[C@@H]3[C@H](CO)O[C@H](O[C@@H]4[C@H](CO)O[C@@H](O[C@@H]5[C@H](CO)O[C@@H](O[C@@H]6[C@H](CO)O[C@@H](O[C@@H]7[C@H](CO)O[C@@H](O[C@@H]8[C@H](CO)O[C@@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:50 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
D13178

# Drug_Target_1_GenBank_ID_Protein:
398125

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
tvaII

# Drug_Target_1_Gene_Sequence:
>1758 bp
ATGCTGTTGGAAGCGATTTTTCATGAAGCGAAAGGAAGCTATGCTTACCCGATTTCGGAA
ACGCAACTGCGGGTGAGATTGCGGGCGAAAAAAGGGGACGTGGTGAGATGCGAGGTGCTC
TATGCGGACCGCTATGCTTCGCCGGAGGAAGAACTGGCACATGCACTTGCGGGCAAAGCA
GGGTCCGATGAGCGATTTGATTATTTTGAGGCTTTACTGGAATGTTCCACCAAACGGGTG
AAATACGTGTTTTTGTTGACAGGCCCACAAGGGGAGGCTGTTTATTTTGGCGAGACCGGT
TTTTCCGCCGAACGGTCTAAAGCGGGGGTGTTCCAATATGCTTACATCCACCGGAGCGAA
GTGTTTACGACACCGGAATGGGCAAAGGAGGCGGTGATCTACCAGATCTTTCCCGAACGT
TTTGCCAATGGGGATCCCAGCAATGATCCGCCGGGAACGGAACAATGGGCCAAAGACGCC
AGACCTCGGCACGACAGTTTTTACGGCGGAGATTTAAAGGGGGTGATCGACCGTTTGCCA
TATTTGGAGGAGTTGGGAGTGACGGCGCTTTATTTTACTCCCATTTTTGCTTCGCCGTCC
CATCACAAATATGATACAGCTGATTATTTGGCGATTGATCCGCAATTTGGGGATTTGCCC
ACCTTTCGGCGTTTGGTGGATGAAGCTCACCGGCGCGGGATCAAAATCATTTTGGATGCC
GTGTTTAACCATGCCGGAGATCAGTTTTTTGCGTTTCGGGATGTTCTGCAAAAGGGAGAA
CAGTCGCGATATAAGGATTGGTTTTTCATCGAGGATTTTCCCGTTTCCAAGACGTCAAGA
ACCAATTATGAAACCTTTGCCGTCCAAGTGCCGGCCATGCCCAAATTGCGGACGGAAAAT
CCGGAAGTGAAGGAATATTTGTTTGATGTCGCGCGATTTTGGATGGAGCAGGGGATCGAC
GGATGGAGACTGGATGTGGCCAATGAGGTGGATCACGCCTTTTGGCGCGAGTTTCGCCGC
CTTGTCAAATCCCTCAATCCCGACGCCTTGATTGTCGGAGAGATTTGGCATGACGCTTCC
GGCTGGCTGATGGGAGACCAATTTGATTCGGTGATGAATTATTTGTTTCGCGAGAGTGTG
ATCCGTTTTTTTGCCACGGGGGAGATCCATGCCGAAAGATTTGACGCCGAACTTACCCGG
GCCAGGATGCTTTATCCGGAACAGGCGGCACAAGGGTTATGGAACCTCCTCGACTCACAC
GATACGGAACGTTTTTTGACATCGTGTGGGGGGAATGAGGCGAAATTCCGCCTGGCTGTT
TTGTTTCAGATGACATACCTGGGGACGCCGCTGATTTATTACGGTGATGAGATCGGGATG
GCCGGAGCGACGGACCCGGATTGCCGGCGCCCGATGATATGGGAGGAAAAAGAGCAGAAC
CGCGGCTTGTTTGAGTTTTATAAGGAATTGATTCGCTTGCGCCATCGGCTGGCATCGCTC
ACCAGGGGAAATGTCCGGTCTTGGCATGCCGACAAACAAGCCAATCTTTATGCTTTTGTG
CGCACGGTTCAAGACCAACATGTCGGTGTGGTTCTCAATAATCGTGGCGAGAAGCAAACC
GTTTTGCTACAGGTGCCGGAATCGGGCGGAAAAACTTGGCTGGATTGTTTGACCGGAGAA
GAAGTGCATGGCAAACAAGGGCAACTGAAGCTGACACTTCGCCCTTACCAGGGAATGATT
CTCTGGAATGGCCGGTAG

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
10222200	Kamitori S, Kondo S, Okuyama K, Yokota T, Shimura Y, Tonozuka T, Sakano Y: Crystal structure of Thermoactinomyces vulgaris R-47 alpha-amylase II (TVAII) hydrolyzing cyclodextrins and pullulan at 2.6 A resolution. J Mol Biol. 1999 Apr 16;287(5):907-21.
12051850	Kamitori S, Abe A, Ohtaki A, Kaji A, Tonozuka T, Sakano Y: Crystal structures and structural comparison of Thermoactinomyces vulgaris R-47 alpha-amylase 1 (TVAI) at 1.6 A resolution and alpha-amylase 2 (TVAII) at 2.3 A resolution. J Mol Biol. 2002 Apr 26;318(2):443-53.
7763540	Tonozuka T, Ohtsuka M, Mogi S, Sakai H, Ohta T, Sakano Y: A neopullulanase-type alpha-amylase gene from Thermoactinomyces vulgaris R-47. Biosci Biotechnol Biochem. 1993 Mar;57(3):395-401.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2606

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
67468

# Drug_Target_1_Name:
Neopullulanase 2

# Drug_Target_1_Number_of_Residues:
585

# Drug_Target_1_PDB_ID:
1VFK

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00128	Alpha-amylase
PF02903	Alpha-amylase_N

# Drug_Target_1_Protein_Sequence:
>Neopullulanase 2
MLLEAIFHEAKGSYAYPISETQLRVRLRAKKGDVVRCEVLYADRYASPEEELAHALAGKA
GSDERFDYFEALLECSTKRVKYVFLLTGPQGEAVYFGETGFSAERSKAGVFQYAYIHRSE
VFTTPEWAKEAVIYQIFPERFANGDPSNDPPGTEQWAKDARPRHDSFYGGDLKGVIDRLP
YLEELGVTALYFTPIFASPSHHKYDTADYLAIDPQFGDLPTFRRLVDEAHRRGIKIILDA
VFNHAGDQFFAFRDVLQKGEQSRYKDWFFIEDFPVSKTSRTNYETFAVQVPAMPKLRTEN
PEVKEYLFDVARFWMEQGIDGWRLDVANEVDHAFWREFRRLVKSLNPDALIVGEIWHDAS
GWLMGDQFDSVMNYLFRESVIRFFATGEIHAERFDAELTRARMLYPEQAAQGLWNLLDSH
DTERFLTSCGGNEAKFRLAVLFQMTYLGTPLIYYGDEIGMAGATDPDCRRPMIWEEKEQN
RGLFEFYKELIRLRHRLASLTRGNVRSWHADKQANLYAFVRTVQDQHVGVVLNNRGEKQT
VLLQVPESGGKTWLDCLTGEEVHGKQGQLKLTLRPYQGMILWNGR

# Drug_Target_1_Reaction:
Hydrolysis of pullulan to panose (6-alpha-D-glucosylmaltose)

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Hydrolyzes pullulan efficiently but only a small amount of starch. Endohydrolysis of 1,4-alpha-glucosidic linkages in pullulan to form panose. Cleaves also (1-6)-alpha-glucosidic linkages to form maltotriose

# Drug_Target_1_SwissProt_ID:
Q08751

# Drug_Target_1_SwissProt_Name:
NEPU2_THEVU

# Drug_Target_1_Synonyms:
Alpha-amylase II
EC 3.2.1.135
TVA II

# Drug_Target_1_Theoretical_pI:
5.89

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Periplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
V00303

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
malE

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_2_General_References:
1420181	Sharff AJ, Rodseth LE, Spurlino JC, Quiocho FA: Crystallographic evidence of a large ligand-induced hinge-twist motion between the two domains of the maltodextrin binding protein involved in active transport and chemotaxis. Biochemistry. 1992 Nov 10;31(44):10657-63.
2002054	Spurlino JC, Lu GY, Quiocho FA: The 2.3-A resolution structure of the maltose- or maltodextrin-binding protein, a primary receptor of bacterial active transport and chemotaxis. J Biol Chem. 1991 Mar 15;266(8):5202-19.
6088507	Duplay P, Bedouelle H, Fowler A, Zabin I, Saurin W, Hofnung M: Sequences of the malE gene and of its product, the maltose-binding protein of Escherichia coli K12. J Biol Chem. 1984 Aug 25;259(16):10606-13.
6088520	Froshauer S, Beckwith J: The nucleotide sequence of the gene for malF protein, an inner membrane component of the maltose transport system of Escherichia coli. Repeated DNA sequences are found in the malE-malF intercistronic region. J Biol Chem. 1984 Sep 10;259(17):10896-903.
6185687	Bedouelle H, Schmeissner U, Hofnung M, Rosenberg M: Promoters of the malEFG and malK-lamB operons in Escherichia coli K12. J Mol Biol. 1982 Nov 15;161(4):519-31.
6283312	Bedouelle H, Hofnung M: A DNA sequence containing the control regions of the malEFG and malK-lamB operons in Escherichia coli K12. Mol Gen Genet. 1982;185(1):82-7.
8265357	Blattner FR, Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL: Analysis of the Escherichia coli genome. IV. DNA sequence of the region from 89.2 to 92.8 minutes. Nucleic Acids Res. 1993 Nov 25;21(23):5408-17.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.
9309217	Quiocho FA, Spurlino JC, Rodseth LE: Extensive features of tight oligosaccharide binding revealed in high-resolution structures of the maltodextrin transport/chemosensory receptor. Structure. 1997 Aug 15;5(8):997-1015.
9600841	Wilkins MR, Gasteiger E, Tonella L, Ou K, Tyler M, Sanchez JC, Gooley AA, Walsh BJ, Bairoch A, Appel RD, Williams KL, Hochstrasser DF: Protein identification with N and C-terminal sequence tags in proteome projects. J Mol Biol. 1998 May 8;278(3):599-608.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3668

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
43388

# Drug_Target_2_Name:
Maltose-binding periplasmic protein precursor

# Drug_Target_2_Number_of_Residues:
396

# Drug_Target_2_PDB_ID:
1LLS

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01547	SBP_bac_1

# Drug_Target_2_Protein_Sequence:
>Maltose-binding periplasmic protein precursor
MKIKTGARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIK
VTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTW
DAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEP
YFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAE
AAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKE
LAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIP
QMSAFWYAVRTAVINAASGRQTVDEALKDAQTRITK

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-26

# Drug_Target_2_Specific_Function:
Involved in the high-affinity maltose membrane transport system malEFGK. Initial receptor for the active transport of and chemotaxis toward maltooligosaccharides

# Drug_Target_2_SwissProt_ID:
P0AEX9

# Drug_Target_2_SwissProt_Name:
MALE_ECOLI

# Drug_Target_2_Synonyms:
MMBP
Maltodextrin-binding protein

# Drug_Target_2_Theoretical_pI:
5.37

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
Not Available

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AF060204

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
Not Available

# Drug_Target_3_Gene_Sequence:
>1767 bp
ATGAGGAAAGAAGCCATCCACCACCGCTCAACCGACAATTTCGCTTATGCTTATGACAGC
GAGACGCTCCATCTCCGGCTTCAAACAAAGAAAAATGATGTCGACCACGTCGAGCTGCTT
TTTGGCGACCCGTACGAATGGCACGATGGCGCCTGGCAGTTTCAAACGATGCCGATGCGG
AAAACGGGGAGCGACGGGTTGTTTGACTATTGGCTCGCCGAAGTCAAACCGCCATATCGA
CGGCTGCGCTATGGGTTTGTGCTTCGAGCTGGGGGCGAGAAACTGGTCTATACGGAAAAA
GGATTTTACCATGAAGCTCCGAGCGACGACACCGCTTACTACTTTTGCTTCCCCTTTCTT
CATCGGGTCGACCTATTCCAAGCGCCGGACTGGGTAAAAGACACAGTATGGTATCAAATT
TTCCCCGAGCGGTTCGCCAACGGCAACCCGGCCATCAGTCCGAAAGGGGCGCGGCCGTGG
GGAAGCGAGGACCCGACGCCGACGAGCTTTTTCGGCGGCGACTTGCAAGGAATCATCGAT
CACCTTGACTATTTGGCTGATCTCGGTATTACCGGCATTTACTTGACGCCGATTTTCCGC
GCACCGTCCAATCATAAATACGACACCGCTGATTATTTTGAAATCGACCCGCACTTTGGG
GACAAAGAGACGTTGAAAACACTTGTCAAGCGCTGCCATGAAAAAGGGATCCGCGTCATG
CTCGATGCAGTCTTCAACCATTGCGGCTATGAGTTTGCCCCGTTTCAAGATGTGCTGAAA
AACGGCGCAGCCTCTCGGTATAAAGATTGGTTCCATATTCGCGAGTTTCCGCTCCAAACC
GAGCCGCGCCCGAACTACGACACGTTTGCGTTCGTGCCGCACATGCCGAAACTCAACACC
GCTCATCCGGAAGTGAAGCGCTACTTGCTTGATGTCGCGACATACTGGATTCGCGAGTTT
GATATTGACGGCTGGCGGCTCGATGTGGCGAACGAAATCGATCATCAATTTTGGCGCGAA
TTCCGGCAGGCAGTGAAGGCGCTAAAGCCCGATGTGTACATTCTCGGCGAGATTTGGCAT
GACGCCATGCCTTGGCTGCGCGGCGACCAGTTTGACGCCGTCATGAACTACCCGTTGGCG
GACGCGGCGCTCCGCTTTTTCGCCAAAGAAGACATGAGCGCCAGCGAGTTTGCCGACCGA
TTGATGCATGTGCTTCATTCCTATCCAAAACAGGTCAACGAAGCGGCGTTTAACTTGCTT
GGCAGCCATGATACACCAAGGCTGCTCACTGTTTGCGGCGGCGACGTCCGCAAAGTGAAG
TTGTTGTTTTTGTTCCAGCTCACGTTCACTGGTTCGCCGTGTATTTACTATGGCGATGAG
ATCGGCATGACGGGTGGAAACGATCCGGAATGCCGGAAGTGTATGGTGTGGGATCCAGAG
AAGCAAAACAAAGAACTGTATGAACATGTCAAGCAACTGATCGCTCTTCGCAAGCAATAT
CGGGCGCTTCGACGCGGCGATGTCGCTTTTCTCACCGCCGATGATGAAGTGAACCATCTT
GTTTATGCAAAAACGGATGGCAATGAAACGGTCATGATCATCATCAACCGGAGCAACGAA
GCAGCAGAAATTCCCATGCCGATCGATGCGCGTGGAAAATGGCTGGTCAACCTTCTGACA
GGGGAGCGGTTCGCTGCAGAGGCGGAAACACTTTGCGTCTCCTTGCCGCCGTACGGGTTT
GTGCTTTACGCGGTCGAAAGCTGGTAA

# Drug_Target_3_General_Function:
Involved in catalytic activity

# Drug_Target_3_General_References:
10103262	Kim TJ, Kim MJ, Kim BC, Kim JC, Cheong TK, Kim JW, Park KH: Modes of action of acarbose hydrolysis and transglycosylation catalyzed by a thermostable maltogenic amylase, the gene for which was cloned from a Thermus strain. Appl Environ Microbiol. 1999 Apr;65(4):1644-51.
10473583	Kim JS, Cha SS, Kim HJ, Kim TJ, Ha NC, Oh ST, Cho HS, Cho MJ, Kim MJ, Lee HS, Kim JW, Choi KY, Park KH, Oh BH: Crystal structure of a maltogenic amylase provides insights into a catalytic versatility. J Biol Chem. 1999 Sep 10;274(37):26279-86.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
5484

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
68211

# Drug_Target_3_Name:
Maltogenic amylase

# Drug_Target_3_Number_of_Residues:
588

# Drug_Target_3_PDB_ID:
1SMA

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00128	Alpha-amylase
PF02903	Alpha-amylase_N

# Drug_Target_3_Protein_Sequence:
>Maltogenic amylase
MRKEAIHHRSTDNFAYAYDSETLHLRLQTKKNDVDHVELLFGDPYEWHDGAWQFQTMPMR
KTGSDGLFDYWLAEVKPPYRRLRYGFVLRAGGEKLVYTEKGFYHEAPSDDTAYYFCFPFL
HRVDLFQAPDWVKDTVWYQIFPERFANGNPAISPKGARPWGSEDPTPTSFFGGDLQGIID
HLDYLADLGITGIYLTPIFRAPSNHKYDTADYFEIDPHFGDKETLKTLVKRCHEKGIRVM
LDAVFNHCGYEFAPFQDVLKNGAASRYKDWFHIREFPLQTEPRPNYDTFAFVPHMPKLNT
AHPEVKRYLLDVATYWIREFDIDGWRLDVANEIDHQFWREFRQAVKALKPDVYILGEIWH
DAMPWLRGDQFDAVMNYPLADAALRFFAKEDMSASEFADRLMHVLHSYPKQVNEAAFNLL
GSHDTPRLLTVCGGDVRKVKLLFLFQLTFTGSPCIYYGDEIGMTGGNDPECRKCMVWDPE
KQNKELYEHVKQLIALRKQYRALRRGDVAFLTADDEVNHLVYAKTDGNETVMIIINRSNE
AAEIPMPIDARGKWLVNLLTGERFAAEAETLCVSLPPYGFVLYAVESW

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
O69007

# Drug_Target_3_SwissProt_Name:
O69007_9DEIN

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
5.86

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB03995
